Form 4: Amicus Therapeutics CDO Exercises Options, Sells Shares

Amicus Therapeutics' Chief Development Officer, Jeff Castelli, exercised stock options and subsequently sold a portion of his common stock holdings.

Summary

• Jeff Castelli, Chief Development Officer of Amicus Therapeutics, Inc. (FOLD), reported transactions on November 24, 2025.
• Castelli exercised stock options to acquire 50,000 shares of common stock at an exercise price of $9.03 per share.
• Concurrently, Castelli sold 76,158 shares of common stock at a weighted average price of $10.1586 per share, with prices ranging from $10.00 to $10.51.
• All reported transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on August 22, 2025.
• Following these transactions, Castelli directly beneficially owns 439,318 shares of common stock.
• All exercised options were fully vested and exercisable as of the transaction date, with an expiration date of January 4, 2026.

Sentiment

Score: 5

Explanation: The filing reports a routine insider transaction (option exercise and subsequent sale) executed under a pre-arranged 10b5-1 plan, which is generally considered neutral in terms of company sentiment.

Positives

• The exercise of stock options by the Chief Development Officer indicates a realization of value from his compensation package.
• The sale price of the shares ($10.1586 weighted average) was higher than the exercise price of the options ($9.03), indicating a profitable transaction for the officer.

Negatives

• The sale of shares by an insider, even under a pre-arranged plan, can sometimes be perceived as a lack of confidence, though it is often for personal financial planning or diversification.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

Insider transactions, such as option exercises and share sales, are common occurrences in publicly traded companies, particularly in the biotechnology sector where executive compensation often includes significant equity components. These transactions are typically part of executives' long-term financial planning and diversification strategies.

Stakeholder Impact

• Shareholders: The sale represents a minor reduction in insider ownership, but the transaction was pre-planned, mitigating concerns about immediate market sentiment.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction involving the exercise of stock options and subsequent sale of shares under a Rule 10b5-1 trading plan. Such pre-planned transactions are common for executive compensation and personal financial management and typically do not signal a change in the company's fundamental outlook or warrant a strong buy/sell recommendation based solely on this information. Investors should consider this as a data point within a broader analysis of the company's financial health and strategic direction.

Keywords

Amicus Therapeutics, FOLD, Insider Transaction, Form 4, Stock Options, Share Sale, Jeff Castelli, Chief Development Officer, 10b5-1 Plan